While Avidity Biosciences Inc has underperformed by -9.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RNA rose by 27.16%, with highs and lows ranging from $56.00 to $21.56, whereas the simple moving average fell by -21.38% in the last 200 days.
On March 13, 2025, Citigroup started tracking Avidity Biosciences Inc (NASDAQ: RNA) recommending Buy. A report published by BMO Capital Markets on March 12, 2025, Initiated its previous ‘Outperform’ rating for RNA. Scotiabank also rated RNA shares as ‘Sector Outperform’, setting a target price of $70 on the company’s shares in an initiating report dated March 07, 2025. H.C. Wainwright Initiated an Buy rating on December 20, 2024, and assigned a price target of $72. RBC Capital Mkts initiated its ‘Outperform’ rating for RNA, as published in its report on November 26, 2024. Goldman’s report from September 24, 2024 suggests a price prediction of $59 for RNA shares, giving the stock a ‘Buy’ rating. Barclays also rated the stock as ‘Overweight’.
Analysis of Avidity Biosciences Inc (RNA)
Further, the quarter-over-quarter increase in sales is 35.57%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Avidity Biosciences Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -33.47% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 15.73, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and RNA is recording an average volume of 1.36M. On a monthly basis, the volatility of the stock is set at 7.01%, whereas on a weekly basis, it is put at 10.46%, with a gain of 3.04% over the past seven days. Furthermore, long-term investors anticipate a median target price of $67.07, showing growth from the present price of $30.48, which can serve as yet another indication of whether RNA is worth investing in or should be passed over.
How Do You Analyze Avidity Biosciences Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.61%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 103.99% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RNA shares are owned by institutional investors to the tune of 103.99% at present.
